Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bilbao
Clinical trial register · Spain

Clinical Trials in Bilbao, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Fundación GECP10 Hoffmann-La Roche7 MedSIR5 Sanofi5 Janssen Research & Development, LLC5
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Bilbao

154 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
DrugCannabidiol
University of Oxford
Phase 3
586
Bilbao, Madrid
2026-12-01
Recruiting
Incyte Corporation
Phase 3
426
Alicante, Barcelona, Bilbao, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga
2026-09-08
Recruiting
Regeneron Pharmaceuticals
Phase 3
35
Bilbao, Barcelona, Cáceres, Murcia, Salamanca
2026-06-11
Recruiting
Early Cognitive Interventions in Digital Format for Cancer Survivors
NCT07729969Cognitive Impairment, Cognitive Change, Cancer
Biogipuzkoa Health Research Institute
Not applicable
110
Bilbao, Galdakao, San Sebastián
2026-06-08
Recruiting
Biobizkaia Health Research Institute
Phase 4
100
Córdoba, Bilbao, Valladolid, Albacete, Barcelona, Madrid, Majadahonda, Oviedo
2026-05-25
Recruiting
Hoffmann-La Roche
Phase 2/3
650
EL Palmar (EL Palmar), San Cristóbal de La Laguna, Bilbao, Barcelona, Granada, Jaén, Madrid, Málaga
2026-05-21
Recruiting
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
DrugTarlatamab
Fundación GECP
Phase 2
37
Albacete, Alicante, Elche, Barcelona, Manresa, Bilbao, Jerez de la Frontera, Lugo
2026-05-20
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Sant Joan Despí, Valencia, A Coruña, Alcorcón, Antequera, Badalona, Barcelona, Bilbao
2026-05-11
Recruiting
i+Med S.Coop.
Not applicable
300
Barcelona, Manresa, Bilbao
2026-04-29
Recruiting
Telecare Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy
NCT07711730Limb-Girdle Muscular Dystrophy, Social Competence, Self Esteem, Health Related Quality of Life
University of Deusto
Not applicable
30
Bilbao
2026-03-01
Recruiting
Biobizkaia Health Research Institute
Phase 3
86
Barakaldo, Bilbao
2026-02-24
Recruiting
SOLTI Breast Cancer Research Group
Phase 2
300
Barcelona, A Coruña, Alicante, Badajoz, Bilbao, Girona, Granada, L'Hospitalet de Llobregat
2026-02-18
Recruiting
Sanofi
Phase 2
144
Bilbao, Barcelona, Seville, Córdoba, Málaga
2025-12-29
Recruiting
UNICANCER
Phase 3
3,902
Badajoz, Barcelona, Bilbao, Fuenlabrada, Granada, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat
2025-12-18
Recruiting
ALX Oncology Inc.
Phase 2
120
Málaga, Seville, Bilbao, Barcelona, Lleida, Madrid
2025-12-10
Recruiting
Boehringer Ingelheim
Phase 3
120
Barcelona, Bilbao, Málaga, Seville
2025-12-09
Recruiting
Biotechnology Institute IMASD
Phase 4
38
Bilbao
2025-11-01
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
DrugAvacincaptad Pegol
ONL Therapeutics
Phase 2
324
Barcelona, Bilbao, Córdoba, Madrid, Seville, Valencia, Zaragoza
2025-10-28
Recruiting
Novo Nordisk A/S
Phase 3
1,280
A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria
2025-10-02
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
413
Barcelona, Bilbao, Córdoba, Huelva, L'Hospitalet de Llobregat, Madrid, Santiago de Compostela, Seville
2025-09-13
Recruiting
Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest
NCT07174986Out of Hospital Cardiac Arrest, Ventricular Fibrillation, Defibrillation, CPR
Gabriel Riva
Phase 2/3
916
Málaga, Bilbao, Barcelona, Madrid
2025-09-08
Recruiting
Pfizer
Phase 3
400
A Coruña, Barcelona, Bilbao, Málaga, Granada, Jaén, Zaragoza
2025-08-05
Active, closed
Boston Scientific Corporation
Observational
550
Bilbao, Madrid
2025-07-30
Recruiting
PALACE: Cemiplimab Trial According to ctDNA Levels
NCT06917573Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer
DrugsCarboplatine·Cemiplimab·Paraplatin·Taxol
Fundación GECP
Phase 2
63
Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, Girona
2025-07-29
Recruiting
Bristol-Myers Squibb
Phase 3
450
Barcelona, Bilbao
2025-07-18
Recruiting
Fundación GECP
Phase 2
97
Alicante, Badalona, Barcelona, Bilbao, Jerez de la Frontera, Girona, Granada, A Coruña
2025-07-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Jaén, L'Hospitalet de Llobregat, Lleida
2025-07-02
By invitation
Universidad de Zaragoza
Observational
100
Bilbao
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
L'Hospitalet de Llobregat, Bilbao, Salamanca, Jaén, Santiago de Compostela, Pozuelo de Alarcón, Valencia, Barcelona
2025-06-30
Active, closed
Immunovant Sciences GmbH
Phase 2
180
Bilbao, Cadiz, Córdoba, Mérida, Valencia
2025-06-30
Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic Myeloid Leukemia
DrugsAsciminib·Nilotinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2
160
Barcelona, Bilbao, Girona, Granada, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca
2025-06-26
Recruiting
AbbVie
Phase 2
180
Sabadell, Seville, Bilbao, A Coruña, Córdoba, Madrid, Valencia
2025-06-20
Recruiting
Bristol-Myers Squibb
Phase 3
274
Barcelona, Bilbao
2025-06-13
Recruiting
Ultrasound-Innovation Medtech, S.L.
Not applicable
457
A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga
2025-05-10
Recruiting
University of Alberta
Phase 3
1,284
Bilbao
2025-05-08
Recruiting
Hoffmann-La Roche
Phase 3
450
Elche, L'Hospitalet de Llobregat, Pamplona/iruña, Bilbao, Barcelona, Madrid, Málaga, Seville
2025-04-09
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Barcelona, Bilbao, Córdoba, Santiago de Compostela, Valencia
2025-03-18
Recruiting
Instituto de Investigación Marqués de Valdecilla
Observational
330
Santander, Alicante, Barcelona, Bilbao, Burgos, Madrid, Oviedo, Toledo
2025-03-01
Recruiting
Amgen
Phase 3
844
Santa Coloma de Gramenet, Córdoba, Bilbao, Madrid, Seville
2025-02-25
Recruiting
Dianthus Therapeutics
Phase 3
256
Barcelona, Alicante, Bilbao
2025-02-10
Recruiting
Fundación GECP
Phase 3
129
Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, A Coruña
2025-02-04
Recruiting
Airway Therapeutics, Inc.
Phase 2/3
366
Alicante, Barcelona, Bilbao, Cadiz, Lleida, Madrid, Málaga, Santiago de Compostela
2025-02-03
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Barcelona, Bilbao, Málaga, Seville
2025-01-10
Active, closed
Pfizer
Phase 3
1,035
A Coruña, Elche, Seville, Barcelona, L'Hospitalet de Llobregat, Eixample, Bilbao, Jerez de la Frontera
2025-01-06
Recruiting
GlaxoSmithKline
Phase 3
514
Bilbao, Barcelona, VigoPontevedra
2024-12-12
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
DrugsElacestrant·Everolimus
MedSIR
Phase 3
300
Barcelona, A Coruña, Alicante, Badalona, Bilbao, Burgos, Castellon, Cáceres
2024-12-05
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga
2024-12-03
Active, closed
ViiV Healthcare
Phase 3
326
L'Hospitalet de Llobregat, Bilbao, Puerto Real, Barcelona, Córdoba, Madrid, Málaga, Murcia
2024-12-02
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
DrugAlisertib
Puma Biotechnology, Inc.
Phase 2
225
Alicante, Barakaldo, Barcelona, Bilbao, Cáceres, Granada, Huelva, Jaén
2024-11-19
Recruiting
Hospital Universitario 12 de Octubre
Not applicable
440
Bilbao, Granada, Huelva, Madrid, Málaga, Seville
2024-11-01
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
600
A Coruña, Alcobendas, Bilbao, Castellon, Madrid, Málaga, Sabadell, Santiago de Compostela
2024-10-15
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
960
A Coruña, Alcobendas, Bilbao, Castelló, Madrid, Málaga, Sabadell, Santiago de Compostela
2024-10-15
Recruiting
Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
NCT06446882HER2-positive Breast Cancer, Early-stage Breast Cancer
Fundacio Clinic Barcelona
Not applicable
304
L'Hospitalet de Llobregat, Granada, Santiago de Compostela, León, Madrid, Murcia, Reus, Bilbao
2024-10-11
Recruiting
Fundación GECP
Observational
50
Ferrol, Alicante, Badalona, Barcelona, Bilbao, Ciudad Real, Girona, A Coruña
2024-10-03
Recruiting
Ferring Pharmaceuticals
Phase 3
250
Santander, Barcelona, Córdoba, A Coruña, Alcorcón, Madrid, Pamplona, Bilbao
2024-10-01
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Santander, Barcelona, Córdoba, A Coruña, Granada, Alcorcón, Madrid, Bilbao
2024-10-01
Recruiting
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
NCT06919341ITP - Immune Thrombocytopenia, Primary Immune Thrombocytopenia (ITP)
Fundación Española de Hematología y Hemoterapía
Observational
1,000
A Coruña, Palma, Barcelona, Terrassa, Bilbao, Torrelavega, Castellon, Algeciras
2024-09-27
Recruiting
GlaxoSmithKline
Phase 1
142
Barcelona, Bilbao, Pamplona, Sabadell Barcelona, Valladolid
2024-09-02
Active, closed
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)
NCT06790238Adenocarcinoma of Stomach, Critical Pathways, Enhanced Recovery After Surgery (ERAS) Protocol, Retrospective Studies
Grupo Español de Rehabilitación Multimodal
Observational
350
Alcázar de San Juan, Barakaldo, Barcelona, Bilbao, Ciudad Real, Fuenlabrada, Guadalajara, Inca
2024-09-01
Recruiting
Alimera Sciences
Phase 4
25
Bilbao, Madrid
2024-08-31
Recruiting
Janssen Research & Development, LLC
Phase 3
752
Barcelona, Bilbao, Collado Villalba, Madrid, Torrevieja
2024-07-25
Active, closed
MedSIR
Phase 2
165
Seville, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Granada, León
2024-07-22
Recruiting
Vor Biopharma
Phase 3
180
Alicante, Barcelona, Terrassa, Bilbao, Valencia
2024-07-17
Recruiting
Fundación IVI
Observational
1,573
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo, Zaragoza
2024-07-17
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Santiago de Compostela, Barcelona, Bilbao, Majadahonda, Pamplona, Oviedo, Sabadell, Santa Cruz de Tenerife
2024-07-12
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Sabadell, Bilbao, A Coruña, Madrid, Seville, Valencia
2024-06-28
Recruiting
Psychosocial Teleassistance Programme for Adults With Spina Bifida
NCT07178873Spina Bifida, Self Esteem, Quality of Life (QOL), Self Concept
University of Deusto
Not applicable
35
Bilbao
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Huelva, Bilbao, Las Palmas de Gran Canaria, Salamanca, Barcelona, Cataluna, Majadahonda, Islas Baleares
2024-06-25
Active, closed
MedSIR
Phase 2
28
Alicante, Barcelona, Bilbao, Córdoba, Granada, Madrid, Seville, Valencia
2024-06-05
Recruiting
PENTA Foundation
Not applicable
3,080
Alicante, Bilbao, Málaga
2024-05-28
Active, closed
Highlight Therapeutics
Phase 2
50
Barcelona, Bilbao, Madrid, Salamanca, Valencia
2024-05-27
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 3
122
Barcelona, Bilbao, El Palmar, Madrid, Pamplona, Salamanca, San Sebastián, Valencia
2024-05-21
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Barcelona, Bilbao, Erandio Bizkaia, Madrid, Valencia
2024-05-20
Recruiting
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Phase 2
51
Zaragoza, Barcelona, L'Hospitalet de Llobregat, Bilbao, Salamanca, Valladolid, Terrassa, Santiago de Compostela
2024-05-16
Active, closed
Sanofi
Phase 3
1,541
Esplugues de Llobregat, Bilbao, Las Palmas de Gran Canaria, Pamplona, Vigo, Seville, Burjassot - Valencia, Alicante
2024-05-08
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Alicante, Barcelona, Bilbao, El Palmar, Galdakao, Granada, L'Hospitalet de Llobregat, Madrid
2024-05-06
Recruiting
Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
NCT07240038Pneumonia Ventilator Associated, Pneumonia Neonatal, Healthcare-associated Infections
Biobizkaia Health Research Institute
Observational
1,500
A Coruña, Santiago de Compostela, Albacete, Badalona, Barcelona, Barakaldo, Bilbao, Burgos
2024-04-26
Active, closed
Amgen
Phase 3
434
Córdoba, Bilbao, A Coruña, Madrid, San Cristóbal de La Laguna, Santa Coloma de Gramenet(Barcelona), Seville, Vitoria-Gasteiz
2024-04-08
Active, closed
MedSIR
Phase 2
976
A Coruña, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Elche, Girona
2024-04-01
Active, closed
Boehringer Ingelheim
Phase 3
428
A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia
2024-02-09
Recruiting
Beatriz Rodriguez Cabo
Observational
40
Bilbao
2024-01-01
Active, closed
argenx
Observational
413
Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Oviedo, Pamplona, San Sebastián
2023-11-29
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Badalona, Sabadell, Bilbao, Santander, Vigo, A Coruña, Barcelona, Córdoba
2023-10-27
Recruiting
Hospital de Basurto
Not applicable
88
Bilbao
2023-10-25
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,295
Albacete, Alicante, Alzira, Barakaldo, Barcelona, Bilbao, Cadiz, Cáceres
2023-10-24
Active, closed
Janssen Research & Development, LLC
Phase 3
684
Alcorcón, Alicante, Barcelona, Bilbao, Madrid, Palma de Mallorca, Santiago de Compostela, Seville
2023-10-12
Recruiting
Acrotech Biopharma Inc.
Phase 3
504
Bilbao, Moncloa-Aravaca, Pamplona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza
2023-10-04
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Barcelona, Bilbao, Granada, Madrid, Seville, Valencia, VigoPontevedra
2023-09-13
Active, closed
AnaptysBio, Inc.
Phase 2
420
Bilbao, Santiago de Compostela, Córdoba
2023-08-31
Recruiting
AstraZeneca
Observational
52,121
A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Las Palmas de Gran Canaria, Madrid, Majadahonda
2023-08-21
Active, closed
Swedish Orphan Biovitrum
Observational
165
Badalona, Barakaldo, Barcelona, Bilbao, Donostia / San Sebastian, El Palmar, Huelva, Las Palmas de Gran Canaria
2023-06-26
Active, closed
ETOP IBCSG Partners Foundation
Phase 2
68
A Coruña, Alicante, Badalona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valencia
2023-06-12
Recruiting
Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer
NCT06889883Colorectal Carcinoma, Advanced Adenomas (AA)
ADVANCED MARKER DISCOVERY S.L.
Observational
510
Zaragoza, Bilbao, Donostia / San Sebastian, Santander, Salamanca, Barcelona, Madrid, Oviedo
2023-06-06
Active, closed
Fundación GECP
Phase 2
22
Alicante, Barcelona, Mataró, Bilbao, Cáceres, Jerez de la Frontera, Girona, Jaén
2023-05-12
Active, closed
Gilead Sciences
Phase 3
654
Barcelona, Bilbao, Córdoba, Elche, Jaén, Madrid, Salamanca, Santiago de Compostela
2023-05-08
Active, closed
Alfasigma S.p.A.
Phase 3
495
Alicante, Barcelona, Bilbao, Córdoba, Madrid, Santander, Santiago de Compostela, Seville
2023-04-05
Active, closed
ETOP IBCSG Partners Foundation
Phase 2
60
A Coruña, Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valladolid
2023-03-27
Recruiting
Regeneron Pharmaceuticals
Phase 3
202
Bilbao, Barcelona
2023-03-07
Active, closed
AstraZeneca
Phase 2
188
Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia
2023-03-06
Active, closed
Pfizer
Phase 3
624
A Coruña, Elche, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Donostia / San Sebastian, Lleida
2023-03-03
Active, closed
Bristol-Myers Squibb
Phase 3
513
Mérida, Barcelona, Bilbao, Santander, Cordoba, Seville, Valencia, Valladolid
2023-01-12
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Barcelona, Valencia, Bilbao, Córdoba, Granada, Madrid, Málaga
2022-12-29
Active, closed
SOLTI Breast Cancer Research Group
Phase 2
120
Badalona, Santa Cruz de Tenerife, A Coruña, Fuenlabrada, Móstoles, Badajoz, Barcelona, Bilbao
2022-11-25
Recruiting
PETHEMA Foundation
Phase 3
480
Alcalá de Henares, Pozuelo de Alarcón, Pamplona, Albacete, Badalona, Barcelona, Bilbao, Burgos
2022-11-10
Active, closed
Fundación GECP
Phase 2
46
Alicante, Badalona, Barcelona, Bilbao, Girona, A Coruña, Lugo, Madrid
2022-11-07
Recruiting
GBG Forschungs GmbH
Observational
400
Córdoba, Bilbao, Santa Cruz de Tenerife, Badalona, Barcelona, Lleida, Sabadell, Cáceres
2022-10-12
Active, closed
Eli Lilly and Company
Phase 3
15,374
A Coruña, Almería, Alzira, Barcelona, Bilbao, Ferrol, Granada, León
2022-10-11
Active, closed
Eli Lilly and Company
Phase 3
8,000
A Coruña, Alicante, Almería, Badajoz, Barcelona, Bilbao, Burgos, Cáceres
2022-10-04
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Alicante, Barcelona, Bilbao, Donostia / San Sebastian, Madrid, Seville
2022-09-23
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville
2022-08-30
Active, closed
Sanofi
Phase 2/3
1,856
Badalona, Bilbao, Las Palmas de Gran Canaria, Pamplona, Pontevedra, Vigo, Seville, Burjassot
2022-08-22
Active, closed
Regeneron Pharmaceuticals
Phase 3
202
Bilbao, Barcelona, Murcia, Salamanca
2022-08-01
Active, closed
Gilead Sciences
Phase 3
443
A Coruña, Barcelona, Bilbao, Lleida, Madrid, Málaga, Murcia, Santa Cruz de Tenerife
2022-07-25
Active, closed
Gilead Sciences
Phase 3
623
A Coruña, Barcelona, Bilbao, Lleida, Madrid, Murcia, Seville, Valencia
2022-07-20
Active, closed
Fundación GECP
Observational
100
A Coruña, Alicante, Badalona, Barcelona, Bilbao, Córdoba, Girona, Pamplona
2022-06-17
Active, closed
Hoffmann-La Roche
Phase 3
1,300
L'Hospitalet de Llobregat, Salt, Santiago de Compostela, Majadahonda, Bilbao, Barcelona, Madrid, Málaga
2022-05-03
Active, closed
Safety and Effectiveness Evaluation of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease
NCT05192616Angioplasty, Peripheral Arterial Disease, Iliac Artery Disease, Covered Stent
iVascular S.L.U.
Observational
241
Barcelona, Bilbao, Sabadell
2022-04-27
Recruiting
Fundación GECP
Phase 2
19
Alicante, Badalona, Barcelona, Bilbao, Girona, Granada, Jaén, A Coruña
2022-03-21
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Ferrol, Madrid, Santander
2022-03-15
Active, closed
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05243550Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
240
Barcelona, Bilbao, Madrid
2022-03-01
Active, closed
Clinical Trial With Artiflex Presbyopic (Artiplus)
NCT04632784Presbyopia, Ametropia, Refractive Errors, Myopia
Ophtec BV
Not applicable
49
Bilbao, Barcelona, Madrid, Seville
2021-11-12
Active, closed
Spanish Breast Cancer Research Group
Phase 3
27
A Coruña, Albacete, Alicante, Badajoz, Badalona, Barcelona, Bilbao, Cadiz
2021-09-14
Active, closed
Janssen Research & Development, LLC
Phase 4
411
A Coruña, Barakaldo, Barcelona, Bilbao, Córdoba, Madrid, Málaga, Sabadell
2021-08-30
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
A Coruña, Algeciras / Cadiz, Barcelona, Bilbao, Córdoba, Granada, Madrid, Oviedo
2021-08-25
Active, closed
MedSIR
Phase 2
393
L'Hospitalet de Llobregat, Córdoba, Reus, A Coruña, Alicante, Badalona, Barcelona, Bilbao
2021-08-05
Recruiting
Janssen Research & Development, LLC
Phase 3
199
Alicante, Barcelona, Bilbao, Seville, Valencia
2021-07-15
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Elche, Badalona, Sabadell, Jerez de la Frontera, Vigo, San Cristóbal de La Laguna, Bilbao, Granada
2021-05-04
Recruiting
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
NCT04796350Fragility Fracture, Hip Fractures, Osteoporosis
AgNovos Healthcare, LLC
Not applicable
2,400
Barcelona, Valladolid, Bilbao, Galdakao, Jaén, Madrid, Manresa, Sabadell
2021-04-24
Active, closed
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
NCT04564157Non-Small Cell Lung Cancer, Adjuvant Chemotherapy
DrugsParaplatin·Taxol·Opdivo·Nivolumab
Fundación GECP
Phase 3
210
Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Cáceres, El Palmar, Girona
2021-01-13
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Santiago Compostela, Málaga, L'Hospitalet de Llobregat, Bilbao, Santander, Vigo, A Coruña, Madrid
2020-12-22
Active, closed
Daiichi Sankyo
Phase 3
1,600
Bilbao, El Palmar, Reus, A Coruña, Alcorcón, Alicante, Badajoz, Barcelona
2020-12-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Pamplona, A Coruña, Badalona, Barcelona, Bilbao, Burgos, Jerez de la Frontera, Las Palmas de Gran Canaria
2020-12-02
Active, closed
Hoffmann-La Roche
Phase 3
210
Bilbao, Badalona, Las Palmas de Gran Canaria, Barcelona, Cáceres, Madrid, Salamanca
2020-10-08
Active, closed
Hoffmann-La Roche
Phase 3
190
Badalona, Santiago de Compostela, Asturias, Bilbao, Barcelona, Madrid, Málaga, Salamanca
2020-09-30
Recruiting
University of Birmingham
Phase 1/2
1,672
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Zaragoza
2020-09-17
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
L'Hospitalet de Llobregat, Majadahonda, Barcelona, Bilbao, Huelva, Málaga
2019-11-26
Recruiting
PETHEMA Foundation
Not applicable
300
Badalona, A Coruña, Albacete, Alicante, Ávila, Barcelona, Bellvitge, Bilbao
2019-11-25
Active, closed
Registry Study of Pregnancy and Breast Cancer
NCT04603820Breast Cancer and Pregnancy
Spanish Breast Cancer Research Group
Observational
866
Palma de Mallorca, Badalona, Terrassa, Bilbao, Santa Cruz de Tenerife, A Coruña, Las Palmas de Gran Canaria, Leganés
2019-11-18
Active, closed
ETOP IBCSG Partners Foundation
Phase 3
405
San Cristóbal de La Laguna, A Coruña, Alicante, Barcelona, Bilbao, Girona, Madrid, Málaga
2019-08-27
Active, closed
Sanofi
Observational
955
Bilbao, Las Palmas de Gran Canaria, Majadahonda, Oviedo, Barakaldo, Barcelona, Madrid, Santiago de Compostela
2019-06-11
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
453
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo
2019-02-08
Recruiting
RECORDATI GROUP
Observational
95
Barcelona, Bilbao, Madrid, Murcia, Palma de Mallorca, Seville, Zaragoza
2019-01-15
Active, closed
PETHEMA Foundation
Phase 3
462
A Coruña, Albacete, Alicante, Badalona, Barcelona, Bilbao, Cáceres, Córdoba
2018-10-22
Active, closed
Fondazione Michelangelo
Phase 3
650
A Coruña, Alcoy, Alicante, Badajoz, Barcelona, Bilbao, Cáceres, Granada
2018-09-07
Active, closed
pharmaand GmbH
Phase 3
1,097
Barcelona, Bilbao, Castillón, El Palmar, Jerez de la Frontera, Madrid, Oviedo, Palma de Mallorca
2018-05-14
Active, closed
PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases
NCT03569241Prostate Cancer, Prostate Cancer Metastatic, Metastatic Cancer, Oligometastatic Cancer
University Hospital, Ghent
Phase 2
196
Barakaldo, Bilbao, Madrid, Navarro, Santiago, Valencia
2018-04-27
Active, closed
AbbVie
Phase 3
1,336
Ferrol, L'Hospitalet de Llobregat, Sabadell, Majadahonda, Bilbao, Barcelona, Madrid, Salamanca
2018-04-09
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
885
Alcorcón, Barcelona, Bilbao, Cartagena, Córdoba, Las Palmas de Gran Canaria, Pamplona, Sabadell
2017-09-25
Recruiting
University College, London
Observational
2,500
Bilbao, Barcelona, Madrid
2017-01-01
Active, closed
ViiV Healthcare
Phase 3
631
A Coruña, Barcelona, Bilbao, Elche Alicante, Ferrol, Granada, La Laguna Santa Cruz, Madrid
2016-10-27
Active, closed
Hoffmann-La Roche
Phase 3
154
L'Hospitalet de Llobregat, Santander, San Cristóbal de La Laguna, Bilbao, Barcelona, Valencia
2015-02-02
Recruiting
Natural History Study of Synucleinopathies
NCT01799915Patients With Synucleinopathies, Neurogenic Orthostatic Hypotension, Pure Autonomic Failure, REM Sleep Behavior Disorder
NYU Langone Health
Observational
800
Bilbao
2011-06
Recruiting
Esteve Pharmaceuticals, S.A.
Observational
500
Barcelona, Bilbao, Reus, Valencia
2008-12-09
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Alcalá de Henares, Bilbao, Granada, Madrid, Majadahonda, Murcia, Salamanca, Santiago de Compostela
2007-06-21
Rows per page Showing 1–154 of 154
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/bilbao

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 154 of those studies with a site in Bilbao.

How many clinical trials are recruiting in Bilbao?

79 of the 154 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 72 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bilbao), 154 studies
PhaseStudiesRecruitingShare
Phase 3722746.8%
Phase 2291318.8%
Observational261516.9%
Not applicable12117.8%
Phase 2/3764.5%
Phase 4653.9%
Phase 1110.6%
Phase 1/2110.6%

Most active sponsors

Lead sponsors with the most studies (Bilbao)
Lead sponsorStudiesRecruiting
Fundación GECP106
Hoffmann-La Roche72
Janssen Research & Development, LLC53
MedSIR51
Sanofi51
Boehringer Ingelheim41
Novartis Pharmaceuticals42
Alnylam Pharmaceuticals31
AstraZeneca32
Biobizkaia Health Research Institute33
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.